BE2011C030I2 - - Google Patents

Download PDF

Info

Publication number
BE2011C030I2
BE2011C030I2 BE2011C030C BE2011C030C BE2011C030I2 BE 2011C030 I2 BE2011C030 I2 BE 2011C030I2 BE 2011C030 C BE2011C030 C BE 2011C030C BE 2011C030 C BE2011C030 C BE 2011C030C BE 2011C030 I2 BE2011C030 I2 BE 2011C030I2
Authority
BE
Belgium
Application number
BE2011C030C
Other languages
French (fr)
Original Assignee
Novartis Ag
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2011C030(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Mitsubishi Tanabe Pharma Corp filed Critical Novartis Ag
Publication of BE2011C030I2 publication Critical patent/BE2011C030I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
BE2011C030C 2003-04-08 2011-09-08 BE2011C030I2 (he)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46121503P 2003-04-08 2003-04-08

Publications (1)

Publication Number Publication Date
BE2011C030I2 true BE2011C030I2 (he) 2023-03-07

Family

ID=32326722

Family Applications (2)

Application Number Title Priority Date Filing Date
BE2004/0180A BE1015972A5 (fr) 2003-04-08 2004-04-07 Composes organiques.
BE2011C030C BE2011C030I2 (he) 2003-04-08 2011-09-08

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BE2004/0180A BE1015972A5 (fr) 2003-04-08 2004-04-07 Composes organiques.

Country Status (42)

Country Link
US (11) US20060275357A1 (he)
EP (5) EP2316431B1 (he)
JP (3) JP5495467B2 (he)
KR (3) KR101367574B1 (he)
CN (2) CN1767819B (he)
AR (3) AR043987A1 (he)
AT (3) ATE414508T1 (he)
AU (1) AU2004228929B2 (he)
BE (2) BE1015972A5 (he)
BR (1) BRPI0409250B8 (he)
CA (2) CA2707750A1 (he)
CL (2) CL2004000745A1 (he)
CY (3) CY1110260T1 (he)
DE (4) DE122011100047I1 (he)
DK (2) DK1613288T3 (he)
EC (1) ECSP056090A (he)
ES (3) ES2320767T3 (he)
FR (2) FR2854073B1 (he)
GB (1) GB2400318B (he)
GR (1) GR1005052B (he)
HK (3) HK1071685A1 (he)
HR (3) HRP20050886B1 (he)
HU (2) HUE028247T2 (he)
IL (3) IL170888A (he)
IS (2) IS2682B (he)
IT (1) ITMI20040682A1 (he)
LU (1) LU91867I2 (he)
MA (1) MA27729A1 (he)
MX (1) MXPA05010860A (he)
MY (1) MY141249A (he)
NO (4) NO329332B1 (he)
NZ (3) NZ586280A (he)
PE (5) PE20130200A1 (he)
PL (2) PL2316431T3 (he)
PT (1) PT1613288E (he)
RU (5) RU2358716C2 (he)
SG (1) SG175449A1 (he)
SI (2) SI2316431T1 (he)
TN (1) TNSN05256A1 (he)
TW (1) TWI332847B (he)
WO (1) WO2004089341A1 (he)
ZA (1) ZA200507394B (he)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1773307T3 (pl) * 2004-07-30 2015-03-31 Novartis Ag Preparaty 2-amino-1,3-propanodioli i ich analogów
CN1891212B (zh) * 2005-07-07 2010-10-13 马启明 一种口服制剂及其制备方法
PT2295049E (pt) 2005-09-09 2015-03-02 Novartis Ag Tratamento de doenças auto-imunes
PT2623113T (pt) 2005-11-09 2017-07-14 Onyx Therapeutics Inc Compostos para inibição de enzimas
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
SI2041158T1 (sl) 2006-06-19 2013-09-30 Onyx Therapeutics, Inc. Peptidni epoksiketoni za inhibicijo proteasomov
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
EP1923058A1 (en) * 2006-09-26 2008-05-21 Novartis AG Coated pharmaceutical composition comprising an S1P agonist or modulator
CN102579387A (zh) * 2006-09-26 2012-07-18 诺瓦提斯公司 包含s1p调节剂的药物组合物
EP1923054A1 (en) * 2006-09-26 2008-05-21 Novartis AG Fast disintegrating pharmaceutical composition comprising an S1P agonist or modulator
AU2011235934A1 (en) * 2006-09-26 2011-11-03 Novartis Ag Pharmaceutical compositions comprising an S1P modulator
EP1923055A1 (en) * 2006-09-26 2008-05-21 Novartis AG Freeze-dried pharmaceutical composition comprising an S1P agonist or modulator
EP1905434A1 (en) * 2006-09-26 2008-04-02 Novartis AG Organic compounds comprising an S1P receptor agonist and their therapeutic use
WO2008124210A1 (en) * 2007-02-14 2008-10-16 Emory University Methods and compositions for treating or preventing infection using leukocyte sequestration agents
ES2644803T5 (es) * 2007-03-29 2024-02-26 Daiichi Sankyo Co Ltd Composición farmacéutica
TWI501773B (zh) 2007-10-04 2015-10-01 Onyx Therapeutics Inc 結晶肽環氧酮蛋白酶抑制劑以及胺基酸酮環氧化物之合成
EP3120833A1 (en) * 2007-10-12 2017-01-25 Novartis Ag Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators
AU2012216630B2 (en) * 2007-10-12 2015-01-22 Novartis Ag Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators
JP5534645B2 (ja) * 2008-01-11 2014-07-02 日医工株式会社 無包装状態において安定性に優れた塩酸サルポグレラート含有経口投与製剤
WO2009099174A1 (ja) 2008-02-07 2009-08-13 Kyorin Pharmaceutical Co., Ltd. アミノアルコール誘導体を有効成分とする炎症性腸疾患の治療剤又は予防剤
AR070842A1 (es) 2008-03-17 2010-05-05 Actelion Pharmaceuticals Ltd Regimen de dosificacion para un agonista de receptor selectivo de s1p1
WO2009155475A1 (en) 2008-06-20 2009-12-23 Novartis Ag Paediatric compositions for treating1 multiple sclerosis
KR101647855B1 (ko) * 2008-06-20 2016-08-11 메르크 파텐트 게엠베하 직접 사출성형가능한 신속 붕해 정제 매트릭스
CA2735037C (en) * 2008-09-04 2016-07-12 Cargill Incorporated Tabletting of erythritol
BRPI0919668A2 (pt) 2008-10-21 2018-05-29 Onyx Therapeutics, Inc. terapia de combinação com epóxi-cetonas de peptídeo
WO2010055027A2 (en) 2008-11-11 2010-05-20 Novartis Ag Organic compounds
AU2013100533B4 (en) * 2008-11-11 2013-12-12 Novartis Ag Crystalline forms of fingolimod HCL
US8530522B2 (en) * 2008-11-11 2013-09-10 Novartis Ag Organic compounds
CA2747427C (en) 2008-12-17 2015-10-13 Daiichi Sankyo Company, Limited Method for producing diamine derivative
WO2010082531A1 (ja) 2009-01-13 2010-07-22 第一三共株式会社 活性化血液凝固因子阻害剤
EP2407457B1 (en) 2009-03-10 2015-04-22 Daiichi Sankyo Company, Limited Process for producing diamine derivative
WO2010104106A1 (ja) 2009-03-13 2010-09-16 第一三共株式会社 光学活性なジアミン誘導体の製造方法
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
TW201102064A (en) * 2009-06-18 2011-01-16 Daiichi Sankyo Co Ltd Pharmaceutical composition having improved dissolution property
US9675566B2 (en) 2009-07-16 2017-06-13 Pathologica Llc Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
US8853147B2 (en) 2009-11-13 2014-10-07 Onyx Therapeutics, Inc. Use of peptide epoxyketones for metastasis suppression
MX2012010017A (es) 2010-03-01 2012-10-01 Onyx Therapeutics Inc Compuestos de para la inhibicion de inmunoproteasomas.
ES2601884T3 (es) 2010-03-19 2017-02-16 Daiichi Sankyo Company, Limited Procedimiento para mejorar la capacidad de disolución de un anticoagulante
JP5692873B2 (ja) 2010-03-19 2015-04-01 第一三共株式会社 ジアミン誘導体の結晶およびその製造方法
EP2560619A2 (en) * 2010-04-22 2013-02-27 Ratiopharm GmbH A method of preparing an oral dosage form comprising fingolimod
CN103080078B (zh) 2010-07-02 2015-02-11 第一三共株式会社 光学活性二胺衍生物盐的制备方法
WO2012070059A1 (en) 2010-11-25 2012-05-31 Shilpa Medicare Limited Fingolimod polymorphs and their processes
WO2012100043A2 (en) 2011-01-19 2012-07-26 Pathlogica LLC Controlled release oral pharmaceutical dosage forms comprising mgbg
AR085749A1 (es) 2011-04-01 2013-10-23 Novartis Ag Formulaciones
EA028950B1 (ru) * 2011-08-01 2018-01-31 Тева Фармасьютикал Индастриз Лтд. Способ получения фармацевтических композиций, содержащих финголимод
ES2673182T3 (es) 2011-08-10 2018-06-20 Daiichi Sankyo Company, Limited Composición farmacéutica que contiene un derivado de diamina
WO2013091704A1 (en) 2011-12-22 2013-06-27 Synthon Bv Pharmaceutical composition comprising fingolimod
RU2482842C1 (ru) * 2012-04-26 2013-05-27 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения
RU2506949C1 (ru) * 2012-06-13 2014-02-20 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
WO2014011695A2 (en) 2012-07-09 2014-01-16 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
RU2496486C1 (ru) * 2012-07-11 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
CA2896977C (en) 2013-01-08 2021-12-07 Pathologica Llc Methods and compositions for treatment of demyelinating diseases
WO2014141298A2 (en) * 2013-03-11 2014-09-18 Astron Research Limited Stable pharmaceutical composition of fingolimod
EP2990055B1 (en) * 2013-04-26 2019-06-05 Kyoto University Composition comprising a sphingosine-1-phosphate receptor 1 agonist for inhibiting formation and/or enlargement of cerebral aneurysm or for shrinking it
WO2013190151A1 (en) * 2013-05-13 2013-12-27 Synthon B.V. Pharmaceutical composition comprising fingolimod
CA2920758A1 (en) * 2013-07-29 2015-02-05 Aizant Drug Research Solutions Pvt Ltd Pharmaceutical compositions of fingolimod
RU2530626C1 (ru) * 2013-10-21 2014-10-10 Ооо "Валента-Интеллект" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
WO2016026461A1 (en) * 2014-08-22 2016-02-25 Sunshine Lake Pharma Co., Ltd. Solid composition of fingolimod and preparation thereof
WO2016042493A1 (en) * 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Pharmaceutical compositions of fingolimod
JP2018502168A (ja) * 2015-01-20 2018-01-25 ハンダ ファーマシューティカルズ エルエルシー 安定な固体フィンゴリモド剤形
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
CA2973540A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
RU2577230C1 (ru) * 2015-04-09 2016-03-10 Общество с ограниченной ответственностью "Лонг Шенг Фарма Рус" Способ получения капсул финголимода гидрохлорида
US9690975B2 (en) 2015-05-28 2017-06-27 Axogen Corporation Quantitative structural assay of a nerve graft
EP3419607B1 (en) 2017-03-29 2019-11-20 Deva Holding Anonim Sirketi Stable formulations of fingolimod
GR1009654B (el) 2018-08-31 2019-11-18 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει εναν ανοσοτροποποιητικο παραγοντα και μεθοδος για την παρασκευη αυτου
DE102018217334A1 (de) * 2018-10-10 2020-04-16 Harbins Ruhr Bioscience, Inc. Sphingoid-Base und/oder Wirkstoff zur Verwendung bei der Prophylaxe und/oder Therapie einer viralen Infektion und/oder viralen Infektionskrankheit oder der Desinfektion, Nahrungsmittel/Nahrungsergänzungsmittel, Futtermittel/Futterergänzungsmittel und Pflanzenschutzmittel
US11298412B2 (en) 2020-07-16 2022-04-12 Harbins Ruhr Bioscience, Inc. Sphingoid compounds for prophylaxis and/or therapy of coronaviridae infection

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7607683A (nl) * 1976-07-12 1978-01-16 Akzo Nv Werkwijze ter bereiding van nieuwe peptiden en peptide-derivaten en de toepassing hiervan.
US4110332A (en) * 1977-05-05 1978-08-29 Chevron Research Company 1-Triorganostannyl-3-organothio-4-substituted-1,2,4-delta2 -triazolidin-5-ones
US4559153A (en) 1983-10-25 1985-12-17 Phillips Petroleum Company Metal working lubricant
US5112616A (en) 1988-11-30 1992-05-12 Schering Corporation Fast dissolving buccal tablet
JP2841857B2 (ja) * 1990-11-29 1998-12-24 田辺製薬株式会社 長期間安定な経口用医薬製剤
DK0627406T3 (da) 1992-10-21 1999-07-12 Taito Co 2-Amino-1,3-propandiolforbindelser og immunundertrykkende midler
KR100358922B1 (ko) 1994-08-22 2003-01-24 미쯔비시 웰 파마 가부시키가이샤 벤젠화합물및그의의약으로서의용도
HU224814B1 (en) 1995-12-28 2006-02-28 Mitsubishi Pharma Corp Use of propane-1,3-diol derivative for the preparation of a medicament useful for the topical treating of inflammatory and immune diseases
US6476004B1 (en) 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
JP2002241272A (ja) * 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
JPH11209277A (ja) * 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
GB9624038D0 (en) 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
DK0990440T3 (da) * 1997-02-27 2009-02-23 Novartis Ag Farmaceutisk sammensætning indeholdende 2-amino-2[2-(4-octylphenyl)-ethyl]-propan-1,3-diol, en lecithin og et saccharid
ATE271028T1 (de) * 1997-04-04 2004-07-15 Mitsubishi Pharma Corp 2-aminopropan-1,3-diol-verbindungen, ihre medizinische anwendung und zwischenprodukte zu ihrer synthese
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
JP3545595B2 (ja) 1998-04-01 2004-07-21 花王株式会社 スフィンゴ糖脂質の製造法
JP4627356B2 (ja) * 1999-06-30 2011-02-09 松森　　昭 ウイルス性心筋炎の予防または治療薬剤
KR20020027463A (ko) * 1999-07-12 2002-04-13 우에노 도시오 스핀고신-1-인산 수용체 아고니스트 또는스핀고신-1-인산을 유효 성분으로서 함유하는 선유화 억제제
SK152003A3 (en) 2000-07-13 2004-07-07 Sankyo Co Amino alcohol derivatives
WO2002018395A1 (en) 2000-08-31 2002-03-07 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
US6953332B1 (en) 2000-11-28 2005-10-11 St. Jude Medical, Inc. Mandrel for use in forming valved prostheses having polymer leaflets by dip coating
JP4012823B2 (ja) 2001-03-26 2007-11-21 ノバルティス アクチエンゲゼルシャフト ２−アミノ−誘導体
US7521192B2 (en) 2001-04-18 2009-04-21 Rigel Pharmaceuticals, Inc. EDG: modulators of lymphocyte activation and migration
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
WO2003020313A1 (fr) 2001-09-04 2003-03-13 Ono Pharmaceutical Co., Ltd. Medicaments contre les maladies respiratoires renfermant un agent de regulation du recepteur de la sphingosine-1-phosphate
EP1431275B1 (en) 2001-09-27 2010-04-07 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivative, addition salt thereof, and immunosuppressant
CN1329372C (zh) 2001-09-27 2007-08-01 杏林制药株式会社 二芳基硫醚衍生物及其加成盐和免疫抑制剂
DE60330047D1 (en) 2002-01-18 2009-12-24 Merck & Co Inc "n-(benzyl)aminoalkyl carboxylate, phosphinate, phosphonate und tetrazole als edg rezeptoragonisten"
EP1469863A2 (en) 2002-01-18 2004-10-27 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists
DE60329073D1 (de) 2002-01-18 2009-10-15 Merck & Co Inc Edg-rezeptoragonisten
CA2473740A1 (en) 2002-01-18 2003-07-31 David Solow-Cordero Methods of treating conditions associated with an edg receptor
RU2396982C2 (ru) * 2004-07-16 2010-08-20 Киорин Фармасьютикал Ко., Лтд. Эффективный способ использования лекарственных средств и способ предотвращения выраженности побочных эффектов

Also Published As

Publication number Publication date
CA2707750A1 (en) 2004-10-21
MY141249A (en) 2010-03-31
US20090203798A1 (en) 2009-08-13
NO20100250L (no) 2006-01-09
NO335120B1 (no) 2014-09-22
CY2011013I2 (el) 2014-04-09
IS8114A (is) 2005-11-01
ITMI20040682A1 (it) 2004-07-06
IL170888A (he) 2010-06-16
PT1613288E (pt) 2009-02-25
IL197578A (he) 2015-10-29
PE20130200A1 (es) 2013-03-09
FR2854073B1 (fr) 2008-03-14
US20170290787A1 (en) 2017-10-12
BRPI0409250B1 (pt) 2017-07-11
PE20131352A1 (es) 2013-11-14
RU2475237C2 (ru) 2013-02-20
PL1613288T3 (pl) 2009-07-31
FR11C0036I2 (fr) 2023-12-29
IL197578A0 (en) 2011-07-31
ZA200507394B (en) 2007-03-28
NO329332B1 (no) 2010-09-27
US20190175527A1 (en) 2019-06-13
HRP20100601B1 (hr) 2016-12-02
FR2854073A1 (fr) 2004-10-29
ATE414508T1 (de) 2008-12-15
GB2400318A (en) 2004-10-13
SI1613288T1 (sl) 2009-04-30
IE20040246A1 (en) 2004-12-15
DE102004016947A1 (de) 2004-10-21
RU2010146697A (ru) 2012-05-27
US20130108675A1 (en) 2013-05-02
GR1005052B (el) 2005-11-30
MXPA05010860A (es) 2006-05-25
GB2400318B (en) 2005-08-10
US20060275357A1 (en) 2006-12-07
US20140255497A1 (en) 2014-09-11
FR11C0036I1 (fr) 2011-10-14
HRP20050886A2 (en) 2006-11-30
SI2316431T1 (sl) 2016-04-29
DK2316431T3 (en) 2016-01-11
RU2475236C2 (ru) 2013-02-20
KR20110005320A (ko) 2011-01-17
BRPI0409250A (pt) 2006-03-28
HUS1100016I1 (hu) 2016-08-29
CY1110260T1 (el) 2014-04-09
CN1767819A (zh) 2006-05-03
ES2556947T3 (es) 2016-01-21
JP2013177404A (ja) 2013-09-09
EP1613288B1 (en) 2008-11-19
HRP20100600A2 (hr) 2011-03-31
KR20050121712A (ko) 2005-12-27
CN1767819B (zh) 2010-07-28
JP2011006461A (ja) 2011-01-13
ES2228282A1 (es) 2005-04-01
EP2319502A1 (en) 2011-05-11
EP2008650A2 (en) 2008-12-31
JP5495467B2 (ja) 2014-05-21
GB0407819D0 (en) 2004-05-12
ECSP056090A (es) 2006-03-01
AT501681A1 (de) 2006-10-15
EP1613288A1 (en) 2006-01-11
AR078781A2 (es) 2011-11-30
RU2005134173A (ru) 2006-09-10
ES2228282B1 (es) 2006-02-16
LU91867I2 (fr) 2011-11-08
MA27729A1 (fr) 2006-01-02
RU2010147000A (ru) 2012-08-10
DE602004017847D1 (de) 2009-01-02
LU91867I9 (he) 2019-01-03
CN101797241B (zh) 2013-03-27
EP2316431A1 (en) 2011-05-04
HK1071685A1 (en) 2005-07-29
DK1613288T3 (da) 2009-03-23
BRPI0409250B8 (pt) 2022-01-18
NO2011016I2 (no) 2012-08-27
TNSN05256A1 (en) 2007-07-10
ES2320767T3 (es) 2009-05-28
IL242037A0 (he) 2015-11-30
JP5543298B2 (ja) 2014-07-09
KR20120101148A (ko) 2012-09-12
IS8885A (is) 2010-02-25
PE20090743A1 (es) 2009-07-17
AR078782A2 (es) 2011-11-30
CY2011013I1 (el) 2014-04-09
TWI332847B (en) 2010-11-11
BE1015972A5 (fr) 2005-12-06
CL2011000450A1 (es) 2011-11-25
RU2358716C2 (ru) 2009-06-20
WO2004089341A1 (en) 2004-10-21
US20140011885A1 (en) 2014-01-09
US8324283B2 (en) 2012-12-04
CL2004000745A1 (es) 2005-02-11
EP2769713A1 (en) 2014-08-27
AT501681B1 (de) 2012-04-15
DE122011100047I1 (de) 2011-12-15
PE20150676A1 (es) 2015-05-17
EP2008650A3 (en) 2011-04-27
AT504853A2 (de) 2008-08-15
DE202004021680U1 (de) 2010-04-22
US20220031609A1 (en) 2022-02-03
AR043987A1 (es) 2005-08-17
CA2521325A1 (en) 2004-10-21
NO334116B1 (no) 2013-12-16
SG175449A1 (en) 2011-11-28
CY1117071T1 (el) 2017-04-05
CN101797241A (zh) 2010-08-11
US20200237690A1 (en) 2020-07-30
NO20131287L (no) 2006-01-09
HRP20100601A2 (hr) 2011-03-31
IS2682B (is) 2010-10-15
EP2316431B1 (en) 2015-09-30
HK1155647A1 (en) 2012-05-25
PE20050396A1 (es) 2005-07-05
HUE028247T2 (en) 2016-12-28
NZ592339A (en) 2012-09-28
NZ586280A (en) 2011-12-22
NO20055231D0 (no) 2005-11-07
US20110105620A1 (en) 2011-05-05
NO2011016I1 (no) 2011-09-19
US20080311188A1 (en) 2008-12-18
NO20055231L (no) 2006-01-09
PL2316431T3 (pl) 2016-09-30
TW200503784A (en) 2005-02-01
GR20040100121A (el) 2004-12-17
AU2004228929A1 (en) 2004-10-21
JP2004307506A (ja) 2004-11-04
KR101367574B1 (ko) 2014-02-25
RU2012148593A (ru) 2014-05-20
HK1091114A1 (en) 2007-01-12
AU2004228929B2 (en) 2008-02-07
NZ542622A (en) 2009-01-31
RU2009105403A (ru) 2010-08-27
CA2521325C (en) 2010-09-14
HRP20050886B1 (en) 2011-01-31

Similar Documents

Publication Publication Date Title
BE2015C007I2 (he)
BE2014C055I2 (he)
BE2014C027I2 (he)
BE2014C003I2 (he)
BE2013C075I2 (he)
BE2013C070I2 (he)
BE2013C067I2 (he)
BE2013C038I2 (he)
BE2013C036I2 (he)
BE2011C030I2 (he)
JP2004038165A5 (he)
JP2003310757A5 (he)
JP2004227098A5 (he)
IN2006CH02676A (he)
BE2015C005I2 (he)
BE2012C053I2 (he)
JP2004026642A5 (he)
JP2004205489A5 (he)
JP2004039632A5 (he)
JP2004052764A5 (he)
JP2004000473A5 (he)
JP2004028331A5 (he)
JP2004087465A5 (he)
BE2015C024I2 (he)
AU2002329412A1 (he)